These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27406083)

  • 1. Obeticholic Acid: First Global Approval.
    Markham A; Keam SJ
    Drugs; 2016 Aug; 76(12):1221-6. PubMed ID: 27406083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Old and new treatments for primary biliary cholangitis.
    Chascsa D; Carey EJ; Lindor KD
    Liver Int; 2017 Apr; 37(4):490-499. PubMed ID: 28371104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Wong LL; Hegade VS; Jones DEJ
    Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
    Levy C
    Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New name and new treatments for primary biliary cholangitits].
    Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
    Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Treatment Options for Primary Biliary Cholangitis.
    Wong KA; Bahar R; Liu CH; Bowlus CL
    Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obeticholic acid (Ocaliva) for primary biliary cholangitis.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):53-55. PubMed ID: 28323811
    [No Abstract]   [Full Text] [Related]  

  • 9. Obeticholic acid in primary biliary cholangitis.
    Erlinger S
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):3-5. PubMed ID: 27825634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elafibranor: First Approval.
    Blair HA
    Drugs; 2024 Sep; 84(9):1143-1148. PubMed ID: 39110316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid for the treatment of primary biliary cirrhosis.
    Trivedi PJ; Hirschfield GM; Gershwin ME
    Expert Rev Clin Pharmacol; 2016; 9(1):13-26. PubMed ID: 26549695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
    Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D;
    N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Treatment Strategies for Primary Biliary Cholangitis.
    Parés A
    Semin Liver Dis; 2017 Feb; 37(1):60-72. PubMed ID: 28201850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
    Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting liver-related serious adverse events in patients with primary biliary cholangitis-related cirrhosis treated with obeticholic acid.
    Londoño MC; Díaz-González Á
    Liver Int; 2022 Nov; 42(11):2356-2359. PubMed ID: 36162085
    [No Abstract]   [Full Text] [Related]  

  • 17. Effective treatment of autoimmune hepatitis-primary biliary cholangitis overlap syndrome with obeticholic acid.
    Castro Limo JD; Romero-Gutiérrez M; Ruiz Martín J
    Rev Esp Enferm Dig; 2020 Sep; 112(9):737. PubMed ID: 32496125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary biliary cholangitis: Old and novel therapy.
    Floreani A; Mangini C
    Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?
    Wetten A; Jones DEJ; Dyson JK
    Expert Opin Pharmacother; 2021 Oct; 22(15):1949-1953. PubMed ID: 34121570
    [No Abstract]   [Full Text] [Related]  

  • 20. Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation.
    Quigley G; Al Ani M; Nadir A
    Dig Dis Sci; 2018 Feb; 63(2):529-532. PubMed ID: 29305737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.